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Enhanced detection of neoantigenreactive T cells targeting unique
and shared oncogenes for personalized
cancer immunotherapy
Rami Yossef,1 Eric Tran,1,2 Drew C. Deniger,1 Alena Gros,1,3 Anna Pasetto,1 Maria R. Parkhurst,1
Jared J. Gartner,1 Todd D. Prickett,1 Gal Cafri,1 Paul F. Robbins,1 and Steven A. Rosenberg1
Surgery Branch, National Cancer Institute, NIH, Bethesda, Maryland, USA. 2Earle A. Chiles Research Institute and the
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Providence Portland Medical Center, Portland, Oregon, USA. 3Medical Oncology Department, Vall d’Hebron University
Hospital, Vall d’Hebron Institute of Oncology (VHIO), Pg. Vall d’Hebron, Barcelona, Spain.

Adoptive cell transfer (ACT) of tumor-infiltrating lymphocytes (TILs) targeting neoantigens
can mediate tumor regression in selected patients with metastatic epithelial cancer. However,
effectively identifying and harnessing neoantigen-reactive T cells for patient treatment remains
a challenge and it is unknown whether current methods to detect neoantigen-reactive T cells are
missing potentially clinically relevant neoantigen reactivities. We thus investigated whether the
detection of neoantigen-reactive TILs could be enhanced by enriching T cells that express PD-1 and/
or T cell activation markers followed by microwell culturing to avoid overgrowth of nonreactive
T cells. In 6 patients with metastatic epithelial cancer, this method led to the detection of CD4+
and CD8+ T cells targeting 18 and 1 neoantigens, respectively, compared with 6 and 2 neoantigens
recognized by CD4+ and CD8+ T cells, respectively, when using our standard TIL fragment screening
approach. In 2 patients, no recognition of mutated peptides was observed using our conventional
screen, while our high-throughput approach led to the identification of 5 neoantigen-reactive T
cell receptors (TCRs) against 5 different mutations from one patient and a highly potent MHC class
II–restricted KRASG12V-reactive TCR from a second patient. In addition, in a metastatic tumor sample
from a patient with serous ovarian cancer, we isolated 3 MHC class II–restricted TCRs targeting the
TP53G245S hot-spot mutation. In conclusion, this approach provides a highly sensitive platform to
isolate clinically relevant neoantigen-reactive T cells or their TCRs for cancer treatment.
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Tumor cells acquire nonsynonymous mutations during tumorigenesis (1). Some nonsynonymous mutations, denoted as neoantigens, can trigger T cell activation via T cell receptor (TCR) engagement with
MHC molecules (HLA, in human) presenting the peptide containing the mutated amino acid (pHLA)
on target cells (2). Recently, we showed in 101 metastatic melanoma patients that reinfusing autologous
tumor-infiltrating lymphocytes (TILs) could mediate a durable complete response (CR) rate and overall
response rate (ORR) of 24% and 56%, respectively (3). Furthermore, adoptive cell transfer (ACT) treatment with selected TILs targeting neoantigens caused significant tumor regression in a small percentage of
metastatic epithelial cancer patients (4–6). One potential explanation for this low response is that the T cells
used for treatment contained a low frequency of tumor-reactive T cells, which may be a consequence of
the overgrowth of nonreactive cells during extensive in vitro culturing of T cells that is required to generate
sufficient T cell numbers for patient treatment. Due to persistent antigen exposure in the tumor microenvironment, TILs often present exhaustion hallmarks and therefore their growth in vitro can be limited (7). In
addition, due to intratumoral heterogeneity, neoantigens targeted by ACT can be expressed subclonally in
the tumor, resulting in tumor escape (8, 9). To address these issues, we are planning a new clinical trial in
which we retrovirally transduce autologous peripheral blood mononuclear cells (PBMCs) with neoantigenreactive TCRs isolated from the patient (NCT03412877). Targeting multiple neoantigens or shared oncogenes may increase our chances of attacking multiple clones of the tumor.

insight.jci.org   https://doi.org/10.1172/jci.insight.122467
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To select TILs for treatment as part of clinical trial NCT01174121, we cut excised tumor(s) into 1- to
2-mm3 fragments, cultured them ex vivo in high-dose IL-2, and tested the TILs from the fragments for
reactivity against neoantigens using peptides or tandem minigenes (TMGs) encompassing the mutations
identified in the tumor. TIL cultures that contain reactive T cells are further expanded and reinfused to the
patient (10, 11). Although several techniques to enrich for reactive T cells have been developed (12–18), the
detection of tumor- or neoantigen-reactive T cells is still challenging. In a number of these methods, T cells
are enriched based on surface marker expression and further expanded and tested (15, 16, 18–20). Gros
et al. and others showed that sorting TILs expressing programmed cell death protein 1 (PD-1) enriched
tumor- and neoantigen-reactive T cells in patients with melanoma. However, several studies showed that
terminally differentiated effector memory cells (Temra) express low levels of PD-1 on their cell surface (21,
22), although these cells were chronically exposed to antigen and may be clinically relevant (23). CD137, a
costimulatory T cell protein, was also suggested as a candidate for reactive T cell enrichment; nevertheless,
while CD137 is expressed on activated CD8+ cells it may not be reliable, as a sole marker, for the enrichment of activated CD4+ cells (15, 24). Importantly, in these enrichment approaches, the cells are expanded
as mixed cultures that could lead to overgrowth by younger, potentially nonreactive cells, thereby diluting
the reactive, exhausted cells in the culture (13, 16–18). An additional method isolated T cells from tumor
and blood using pHLA tetramers, but this method was restricted to CD8+ cells and relied on predictions of
peptide-HLA binding (12).
In the present study, we developed a nonbiased, 2-step, high-throughput limiting-dilution approach for
detection and isolation of neoantigen-reactive T cells that can potentially overcome some of the problems
discussed above. This approach enabled the enhanced detection of neoantigen-reactive TILs in metastatic
nonmelanoma tumor samples and the rapid isolation of neoantigen-reactive TCRs for potential use in
clinical trials. In this method, we FACS isolated TILs that expressed T cell costimulatory markers (CD134
or CD137) and/or PD-1. We reasoned that the use of both markers would enhance the enrichment of
neoantigen-reactive CD4+ cells that would otherwise be missed by enriching TILs using CD137 alone and
Temra cells that express low levels of PD-1. Sorted cells underwent limiting-dilution cloning and were then
expanded in microwell plates to avoid overgrowth of nonreactive young cells at the expense of exhausted
reactive cells. Cultures that grew were tested against 25mer peptides encompassing mutations that were
present in patient tumors. Employing this approach enabled us to detect 19 neoantigen T cell reactivities
in 6 epithelial cancer samples. Moreover, CD4+ T cells reactive against KRASG12V and TP53G245S hot-spot
mutations were isolated from 2 patients. Notably, reactive cultures were highly oligoclonal or clonal, which
allowed us to efficiently sequence reactive TCRs using single-cell PCR (scPCR). This strategy provides a
sensitive approach for the enhanced detection of neoantigen-reactive TILs and can be utilized for the rapid
identification of neoantigen-reactive TCRs, which can be used to generate a personalized, neoantigentargeted TCR-gene therapy for patients with cancer.

Results
Developing a high-throughput TIL microwell culture method to detect and isolate neoantigen-reactive TCRs. The scheme
we used to isolate neoantigen-reactive TILs is shown in Figure 1. Metastatic lesions were excised from cancer
patients, enzymatically digested to obtain a single-cell suspension, and incubated overnight in T cell medium
without cytokines. Cells were then stained and T cells were FACS isolated based on the expression of PD-1
and/or T cell activation markers (single positives and double positive, Figure 1). Enriched cells were cultured
at low concentration in rapid expansion protocol (REP) conditions in the presence of irradiated allogeneic
feeder cells, IL-2, and OKT3 antibody, as described in detail in the Methods (Figure 1). Three to 4 weeks
later, neoantigen reactivity of the expanded cells was tested based on IFN-γ secretion and expression of T cell
activation markers after coculture with autologous antigen-presenting cells (APCs) expressing the patient’s
own neoantigens as described in the Methods. Briefly, to decrease the number of microcultures screened, cells
from 2 cultures that grew were combined and cocultured with patient’s DCs pulsed with 2 pools of 25mer
peptides containing the nonsynonymous mutations expressed in the patient’s tumor flanked by 12 amino
acids of the wild-type (WT) protein (Figure 1 and ref. 25). Cultures that showed specific reactivity against
the pools, defined by 2-fold higher IFN-γ secretion or upregulation of activation markers compared with the
negative controls, were further expanded for testing (Figure 1). Additionally, cells from coculture wells that
showed reactivity against peptide pools in IFN-γ ELISPOT assays were collected, stained, and FACS isolated
based on activation markers in 96-well plates for single-cell TCR sequencing (Figure 1).
insight.jci.org   https://doi.org/10.1172/jci.insight.122467
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Figure 1. Illustration of the new high-throughput
approach for enrichment, culturing, and screening
strategy of TILs. (1) Tumor cell digests were thawed
and rested overnight in complete media in the absence
of exogenous cytokines. (2a) A piece of the tumor
underwent whole-exome sequencing (WES) and RNA
sequencing to identify nonsynonymous mutations.
Based on mutation calls, 25mer peptides encompassing the mutations at position 13 were synthesized.
(2b) Cells were washed, labeled, and sorted based
on PD-1 and/or activation markers (CD134 or CD137)
expression (pink area represents that gate used in the
sort). (3) Sorted cells were cultured in 96-well plates
at 3 cells/well in the presence of irradiated allogeneic
feeder cells, 3,000 IU/ml IL-2, and anti-CD3ε (OKT3)
for expansion. (4) Peptide pools were pulsed on
autologous APCs that served as a target in a coculture
with sorted cells that grow in the microwell cultures.
To minimize the assays, cells from 2 or 3 cultures
were combined in the assay wells. (5a) Cultures that
showed recognition against peptide pools were further
expanded for future testing. (5b) Cells from Pt.4097
coculture assay were labeled and reactive T cells were
single-cell sorted into 96-well plates containing lysis
buffer and PCR primers for TCR sequencing.

Enhanced detection and isolation of neoantigen-reactive TILs in metastatic epithelial tumors. To test the feasibility
and sensitivity of our high-throughput culturing approach to detect neoantigen-reactive TILs, we studied a metastatic lesion from the adrenal gland in a patient with metastatic gastroesophageal junction adenocarcinoma
(Pt.4078). This patient was enrolled in the NCT01174121 study for possible treatment using ACT with neoantigen-reactive TILs. Neoantigen-reactive T cells were not detected in TILs when tumor fragments were screened
using our standard method (Supplemental Figure 1A; supplemental material available online with this article;
insight.jci.org   https://doi.org/10.1172/jci.insight.122467
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Figure 2. Sorting strategy, functional screen assays, and identification of neoantigen-reactive TCRs in Pt.4078. (A) Gating strategy used in flow
cytometry–based sort for CD3+PD-1+ and/or CD134+ TILs. (B–D) ELISPOT assays measuring IFN-γ secretion of microwell cultures upon coculture with
target cells. (B) Following expansion, pools of 2 cultures were tested against autologous DCs pulsed with 2 peptide pools (PP), indicated by symbols.
(C) Cultures from the reactive pools were tested separately against autologous DCs pulsed with all suspected peptide pools. (D) IFN-γ ELISPOT and
CD137 flow cytometry analysis showing reactivity of the TIL cultures following coculture with autologous DCs pulsed with single 25mer peptides from
each peptide pool. (E) Allogeneic T cells retrovirally transduced with neoantigen-reactive TCRs cocultured with autologous DCs pulsed with serially diluted mutated and WT 25mer peptides. ‘>’ denotes greater than 500 spots. All data are representative of at least 3 independent experiments except in A.

https://doi.org/10.1172/jci.insight.122467DS1). We then used the frozen tumor digest as a source of TILs by
FACS isolating the CD3+PD-1+ and/or CD3+CD134+ subset (Figure 2A). Cells (1.5 × 103) were sorted, diluted
to 3 cells/well, and cultured in REP conditions. Three weeks later, 64 cultures, labeled W1–W64, grew (~13%
growth efficiency) and were tested for reactivity against 104 25mer peptides grouped in 7 peptide pools (PP1
through PP7; Supplemental Table 3). Eight cultures showed substantial reactivity against several peptide pools
(Figure 2B); however, the observation that TILs from W59 and W60 showed recognition of multiple peptide
pools suggested that there was some peptide cross contamination across some peptide pools.
The 8 reactive cultures were further expanded using the REP and retested against PP1 through PP6
(Figure 2C). At this stage, the functional coculture assays showed that 5 cultures (W7, W8, W18, W60,
and W62) recognized unique peptide pools. Interestingly, culture W8 showed specific IFN-γ secretion
when tested against PP1 that was not detected in the first screen, which might be attributable to insufficient peptide presentation on the DCs due to a large number of peptides tested in the first screen (30
peptides were used in the first screen; Figure 2B).
Next, we sought to identify the neoantigens recognized by microwell TIL cultures. To this end,
we performed T cell cocultures against DCs pulsed with individual peptides derived from the relevant
insight.jci.org   https://doi.org/10.1172/jci.insight.122467
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Table 1. TRBV sequences of neoantigen-reactive cultures and their frequency in tumor digest subsets
Culture

CD4/CD8

Mutated gene

W7

CD4

PLXNB3

W8

CD4

DLAT

W18

CD8

GBAS

W60

CD4

TMPRSS4

W62

CD4

PSMD2

CDR3β

TRBV6-1*01
CASNLQRAVNTEAF
TRBV2*01
CASTGANVLTF
TRBV2*01
CASSETGWGAF
TRBV7-2*01
CASSSSGAFQPQHF
TRBV25-1*01
CASRGVGGGTEAF

Frequency in tumor digest

Bulk

PD-1+

PD-1–

0.011

ND

0.0373

ND

0.06

ND

0.0009

0.092

ND

0.0078

0.98

ND

0.026

1.68

ND

ND, not detected.

peptide pools (Figure 2D). Both IFN-γ secretion and upregulation of T cell activation markers assessed
by flow cytometry demonstrated that each TIL culture was reactive solely against 1 potential neoantigen. Also, by coculturing W18 with COS7 cells transfected with the predicted or control HLAs and
pulsed with the predicted minimal epitope, we were able to determine the restriction of the reactivity
(HLA-A*30:01, Supplemental Figure 1B). At this point, we were able to sequence TCRα and TCRβ of
the reactive cultures using 5′RACE rapid cDNA amplification, using TCRα- and TCRβ-specific primers, followed by Sanger sequencing. All 5 cultures displayed unique and clonal TCRs (Table 1). To
verify that the sequences of the α and β chain are indeed encoding for neoantigen-reactive TCRs, we
first cloned the sequences into a retroviral vector (pMSGV1) and introduced the TCRs into allogeneic
PBMCs, as described previously (13). Subsequently, coculture of the TCR-gene-modified cells with
autologous APCs pulsed with a serial dilution of HPLC-grade mutated and counterpart WT peptides
confirmed that the isolated TCRs were neoantigen reactive (Figure 2E).
To evaluate the sensitivity of our new high-throughput approach we determined the frequencies
of the neoantigen-reactive TCRβ sequences in the tumor digest. For this purpose, we performed TCRβ
deep sequencing of the bulk tumor digest and 4 FACS-isolated subsets of the tumor digest: CD4+PD-1+,
CD4+PD-1–, CD8+PD-1+, and CD8+PD-1–. Frequencies of the neoantigen-reactive TCRs in the bulk population were extremely low, ranging from 0.026% to 0.0009% (Table 1), which may at least partially explain
why no neoantigen reactivity was detected using the TIL fragment screen approach. Moreover, 4 out of
the 5 TCRs were detected in the PD-1+ subsets and only one, W7, was detected in the PD-1– subset, suggesting that it likely came from the PD-1–CD134+ population, which is consistent with our previous observations that sorting PD-1+ T cells from tumor digests enriches for tumor- and neoantigen-reactive T cells
(13). Nevertheless, in some cases like culture W7, enrichment for PD-1+ alone is insufficient to isolate all
neoantigen-reactive T cells. However, this could be overcome by using other T cell activation markers,
such as CD134. In summary, we were able to detect T cell reactivities against 5 neoantigens that were not
detected when multiple TIL fragments from the same lesion were tested. Moreover, we were able to isolate
rare neoantigen-reactive TCRs.
To assess the reproducibility of our approach, we employed our new high-throughput multiwell culturing
protocol to screen 5 additional metastatic tumor digest samples from cancer patients with various histologies. All
subjects were previously screened using the tumor fragment screening approach, as part of the NCT01174121
trial (Table 2 and Supplemental Table 1). Using our high-throughput multiwell culturing approach we were
able to detect TIL reactivities in all 5 additional cases. In total, we were able to detect neoantigen reactivities
against 19 different neoantigen targets as compared with 9 that were detected using TIL fragment screening
(Table 2, Supplemental Table 2, and Supplemental Figures 2–5). In the new approach, CD4+ and CD8+ T
cells targeting 18 and 1 neoantigens, respectively, were found, while 6 and 2 neoantigens recognized by CD4+
and CD8+ T cells, respectively, were detected using the standard TIL fragment screening method. Out of the 6
neoantigen reactivities targeted by CD4+ T cells identified using the TIL fragment screening approach, 5 were
identified in our new method. Overall, these results demonstrate the reproducibility and the high sensitivity of
our new culturing and screening approach.
insight.jci.org   https://doi.org/10.1172/jci.insight.122467
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Table 2. Summary of neoantigen reactivities found using the new approach compared with reactivities found in TIL fragments
Patient ID

AgeA/Sex

Tumor histology

No. of mutations
assessed

Reactivities
found in TIL
fragment screenB

4078

48/M

Gastroesophageal
junction
adenocarcinoma

104

None

T cell type

4097

59/F

Ovarian

317

HIST1H1BA71D
INPP5KL176V

CD4
CD4

4148
4217

68/F
49/M

Endometrial
Colon

108
176

4127

58/F

Ovarian

180

None
MAP3K2S153F
UEVLD-1/2F191V
RAD51BL202R
MUC4R4435S
TP53G245S

CD4
CD4
CD4
CD8
CD4

4166

40/M

Pancreatic

156

NPLOC4I312V

CD8

Total:

8

CD8: 2
CD4: 6

Reactivities
found in LD
culturesB

T cell type

No. of reactive
TCRs found using
LDC

GBASE207K

CD8

1

PLXNB3W609G
DLATG294L
TMPRSS4H233Y
PSMD2G644A
HIST1H1BA71D
HYAL4R94S
HSPG2H3568L
KRASG12V
MAP3K2S153F
UEVLD-1/2F191V
RAD51BL202R
TBCKR747S
TP53G245S
HIST1H2BME77V
GORASPL248FS‡
TUBA1BS287T
ZNF727H163Q
TNCE743D
19

CD4
CD4
CD4
CD4
CD4
CD4
CD4
CD4
CD4
CD4
CD4
CD4
CD4
CD4
CD4
CD4
CD4
CD4
CD8: 1
CD4: 18

1
1
1
1
7
1
1
1
1
3
3 (2 + 1)
1
3
1
3 (2 + 1)
1
1
4

At the time of admission. BNeoantigen specificity was determined by testing against WT peptides. CTCRs that were constructed and tested are bolded.
‡FS, frame-shift mutation. LD, limiting dilution.

A

Rapid identification and sequencing of neoantigen-reactive TIL TCRs. For metastatic cancer patients, the time
to clinical intervention is critical. In our attempt to shorten the time of isolation of neoantigen-reactive TCRs,
we utilized scPCR in our screening pipeline to detect reactive TILs, as previously described (15). To investigate the feasibility of incorporating this approach early in the microwell screens we studied cryopreserved cell
digests of a metastatic right groin lymph node from a patient with serous ovarian carcinoma (Pt.4097). Following the in vitro expansion of microwell cultures containing CD3+PD-1+ and/or CD134+ cells, a functional
assay was carried out, as described above (Figure 3A). Following the incubation coculture, we transferred the
cells from the ELISPOT plate into new 96-well plates. After we developed the IFN-γ ELISPOT assay plates
we stained the cells from coculture wells that showed enhanced IFN-γ secretion and sorted single T cells
that upregulated T cell activation markers into 96-well PCR plates for TCR sequencing (Figure 3B). Several
microwell TIL cultures showed recognition against PP15+16, while only 2 coculture wells showed recognition against DCs pulsed with PP1+2 or PP17+18, respectively. Similar to previous screens, for further study
of the reactivities against mutated peptides, putative TIL microwell cultures were further expanded for 2
weeks. However, following the first coculture assay, we were able to obtain unique TCR sequences of the reactive wells with our scPCR method combined with Sanger sequencing (Figure 3C). Next, following expansion,
we studied the reactivities of the single TIL microwell cultures against APCs pulsed with single peptide pools
and the individual peptides (Figure 3D). After we identified the neoantigens, we sequenced the TCRs of the
reactive cultures using TCRβ deep sequencing and confirmed the sequences that were obtained using scPCR.
In summary, we were able to identify and sequence neoantigen-reactive TCRs 4 weeks after we seeded the
microwell TIL cultures. This rapid and reliable approach could be valuable for our clinical trial seeking to
improve the efficacy of personalized cancer immunotherapy treatment with ACT using PBMCs genetically
modified to express neoantigen-reactive TCRs.
Isolating TP53 hot-spot driver mutation–reactive TCRs. The overwhelming majority of cancer-associated
mutations are private and unique to the individual, which means that the targeted neoantigens expressed in
insight.jci.org   https://doi.org/10.1172/jci.insight.122467
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Figure 3. Rapid sequencing of neoantigen-reactive TCRs from Pt.4097. (A and B) Pools of TIL cultures incubated with DCs pulsed with pooled peptide
pools (PP), indicated by symbols. (A) Summary of TIL culture pools showing secretion of IFN-γ in ELISPOT. (B) Cells from ELISPOT coculture wells were
collected, labeled, and single cells expressing T cell activation markers were sorted (as shown in the bottom right panel) into a 96-well PCR plate containing lysis buffer and PCR primers for TCRα and -β. (C) CDR3β of the sequenced culture well. Bolded are the origin of the reactive TCR, based on functional
assays done with the individual cultures (data not shown). (D) Expanded cultures from the indicated TIL microwells coincubated with autologous DCs
pulsed with single peptides from the pools that the cultures showed recognition against in previous experiments, representative of at least 2 independent
experiments. ‘>’ denotes greater than 500 spots.

one patient are not likely to be expressed in other patients. Moreover, due to intratumoral heterogeneity, private mutations might be subclonal. On the other hand, public or shared hot-spot mutations are more likely
to be expressed by all cells within a tumor as well as across tumor samples and histologies. Thus, ACT using
off-the-shelf TCRs targeting shared mutations when possible appears to be an additional attractive strategy
to target cancer neoantigens.
To this end, we employed our approach to screen for neoantigen reactivities in Pt.4127, a metastatic ovarian cancer patient whose tumor expressed a hot-spot mutation in the TP53 gene. In a previous study, CD4+
T cells reactive to the TP53G245S hot-spot mutation were detected when TIL fragments were tested against
peptides and TMGs encoding patient’s nonsynonymous mutations, and 3 TCRs targeting this mutation were
isolated from TIL fragments (26). Here, to screen for neoantigen-reactive TILs we utilized the sorting strategy
that was described in Figure 1 and Figure 2A. We sorted 3,300 cells expressing CD3+PD-1+ and/or CD134+
(denoted with “O”), and 1,320 cells expressing CD3+PD-1+ and/or CD137+ (denoted with “B”) and cultured
them at 3 cells/well in REP conditions. Three weeks later, growth efficiencies for CD3+PD-1+ and/or CD134+
and CD3+PD-1+ and/or CD137+ were 12% and 7%, respectively. In addition to identifying CD4+ T cells that
recognized 3 patient-specific neoantigens that were not detected with the standard TIL fragment screening
method (Supplemental Figure 2), our new culture method also detected multiple microcultures that recognized the TP53G245S hot-spot mutation (Figure 4, A and B).
To further characterize the TP53G245S-reactive TCRs, we first sequenced the TCRs from cultures O37,
O71, and O102, using 5′RACE. The α and β chains were subcloned into a retroviral plasmid and transduced
into allogeneic donor PBMCs. To determine the HLA restriction of the TCRs, we coincubated the TCRtransduced PBMCs with COS7 cells transiently expressing the patient’s HLA class II molecules and pulsed
with mutated TP53 peptide. Interestingly, the recognition of all 3 TCRs was restricted to HLA-DRB3*02:02
insight.jci.org   https://doi.org/10.1172/jci.insight.122467
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Figure 4. Isolation and characterization of 3 TP53G245S neoantigen-reactive TCRs from Pt.4127 sorted TIL microwell cultures. TILs from tumor digest
were sorted and expanded based on the expression of PD-1 and/or CD134. (A) Cells from 2 cultures were combined and cocultured with DCs that were
pulsed with pools of mutated peptides. Showing cultures displayed enhanced IFN-γ secretion against peptide pools 9 and 10 (pool 9 encompassing TP53
mutated peptide) in (B) IFN-γ ELISPOT assay at 16 hours. Following expansion, 2 × 104 cells from individual TIL cultures that showed specific reactivity
against peptide pool 9 (not shown) were cocultured with 1 × 105 DCs pulsed with single peptides present in the pool. (C and D) TCRs targeting TP53G245S
were sequenced, synthesized, and virally delivered into allogeneic PBMCs to assess reactivity and specificity. (C) TCR-transduced cells were coincubated
with COS7 cells that were transfected with plasmids encoding the patient’s HLA class II and pulsed with mutated 25mers. (D) Cells were coincubated
with autologous DCs pulsed with serially diluted TP53G245S and WT peptides. ‘>’ denotes greater than 500 spots. All data are representative of at least 2
independent experiments except in A.

(Figure 4C), which is expressed in up to 33% of White individuals in the US (www.allelefrequencies.net).
Finally, to test the avidity of recognition, we cocultured TCR-transduced cells with autologous DCs pulsed
with a serial dilution of mutated and WT peptides (Figure 4D). Although all 3 TCRs had higher avidity for
the mutated peptide compared with the WT peptide, the TCR isolated from the O37 culture showed greater
specificity against the mutated peptide compared with the other 2 TCRs. Due to the high allele frequency
of HLA-DRB3*02:02, the frequency of the mutation (2.8% of all tumors; see ref. 27), and high specificity
of the receptor, the TCR isolated from O37 might be attractive as an off-the-shelf reagent that could be used
in TCR-gene therapies for patients with metastatic cancer. Altogether, using our high-throughput method
we were able to detect and isolate multiple TCRs from CD4+ cells targeting 4 neoantigens. Three of these
neoantigens were not detected when TIL fragments were tested.
Isolation of a highly potent KRASG12V-targeting TCR. Encouraged by our ability to isolate TCRs targeting the TP53G245S hot-spot mutation and given that KRAS mutations, mainly at positions 12 and 13, are
highly prevalent (28, 29), we sought to use our high-throughput culturing approach to identify neoantigenreactive T cells in tumors expressing KRAS driver mutations. For this purpose, we used cryopreserved
tumor digest from Pt.4148 to prepare the microwell cultures. Pt.4148, a metastatic endometrial cancer
patient, was enrolled in NCT01174121 and her tumor TIL fragments were screened for neoantigen reactivities. No reactivity was found against the peptide pools or against the KRASG12V 24mer, which was pulsed
insight.jci.org   https://doi.org/10.1172/jci.insight.122467
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Figure 5. Characterization of a highly potent HLA-DRB1*07:01–restricted TCR isolated from a metastatic lesion of endometrial cancer. CD3+PD-1+ and/
or CD134+ TILs were sorted, expanded at 3 cells/well, and cultures that grew were tested. (A) TIL microwell culture that showed recognition against DCs
pulsed with pooled peptide pools (PP) were expanded and IFN-γ secretion was assessed following coculture for 16–20 hours with DCs pulsed with single
peptide pools, and (B) single peptides from PP1. (C and D) The functionality of autologous PBMCs virally transduced with the TCR isolated from neoantigen-reactive culture was measured following incubation with (C) DCs liposomally transfected with full-length RNA encoding for KRASWT, KRASG12V, and
KRASG12D, and (D) DCs loaded with supernatant from lysed cell lines that underwent 5 cycles of freezing and thawing at 1:5:10 ratio (T cells/DCs/cell lines).
(E) Autologous DCs pulsed with the mutated peptide were incubated with HLA-blocking antibodies for 2 hours prior to the addition of the PBMCs expressing the TCR. (F) Effector cells expressing the TCRs were incubated with DCs (pulsed with the mutated peptide) from donors matched at one of the DRB1
alleles or with DCs from a complete DRB1 mismatch. ‘>’ denotes greater than 500 spots. All data are representative of at least 3 independent experiments.

individually in the screen (data not shown). Therefore, we used our high-throughput screening method to
test whether we could identify neoantigen-reactive T cells. We sorted 1,720 CD3+PD-1+ and/or CD134+
TIL cells, expanded them at 3 cells/well, and 76 cultures were screened 3 weeks later (~13.5% growth efficiency) against 6 peptide pools (Supplemental Table 4). Only 1 microwell CD4+ culture, W7, demonstrated
enhanced IFN-γ secretion when tested against peptide pools (Figure 5A). Deconvolution of the peptides
from PP1 showed PP1-17, a 24mer peptide encompassing the KRASG12V mutation, as the potential neoantigen targeted by W7 (Figure 5B). The TCR from culture W7 TIL microwell culture was Sanger sequenced
and revealed unique α and β chains that were subcloned into a retroviral expression plasmid and transduced
into autologous PBMCs for further testing. Interestingly, the TCR sequence was present at a very low frequency (0.056%) in the tumor digest and ranked 287 based on TCRβ deep sequencing.
In order to test the specificity of the receptor, autologous DCs were liposomally transfected with RNA
expressing full-length WT KRAS, KRASG12D, or KRASG12V, washed, and cocultured with transduced
PBMCs expressing the receptor. Both cell surface upregulation of CD137, assessed by flow cytometry,
and IFN-γ secretion demonstrated high specificity of KRASG12V recognition (Figure 5C). Since the TCR
was isolated from CD4+ cells, the TCR more likely recognized a mutated protein that was presented by
MHC II molecules expressed by APCs that had taken up the antigen from apoptotic cancer cells in the
tumor microenvironment or draining lymph nodes. Thus, to test whether this TCR could recognize tumor
lysates derived from KRASG12V-expressing cancer cells, we cocultured TCR-transduced cells with autologous DCs loaded with supernatant from cell lysates originating from mutated-KRAS-expressing cell lines
(5:1 ratio of DC/cell lines) including the TC4177, KRASG12V-expressing line established from a pancreatic lesion in our laboratory. KRASG12V TCR–transduced cells demonstrated specific recognition against
autologous DCs loaded with lysates from KRASG12V-expressing cell lines but not KRASG12D, KRASG12C,
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KRASG12R or WT, as demonstrated in Figure 5D. Furthermore, coincubation of gene-engineered T cells
expressing the receptors with autologous DCs pulsed with a serial dilution of the 24mer peptide demonstrated coreceptor-independent activation of CD8+ cells (Supplemental Figure 3, C and D).
To determine which HLA allele presented the mutated KRASG12V epitope, we incubated autologous
DCs loaded with KRASG12V peptides in the presence of HLA-blocking antibodies and then performed
cocultures with autologous peripheral blood lymphocytes (PBLs) transduced with the TCR. Although
blocking HLA-II with anti–pan class II antibody slightly reduced CD137 expression, blocking HLA-DR
showed a substantial reduction in IFN-γ secretion and CD137 cell-surface expression (Figure 5E). To
determine the specific allele that presented the KRASG12V peptide, we pulsed the 24mer peptide on DCs
from donors expressing either one of the patient’s HLA-DRB1 alleles or donor DCs with complete allele
mismatch; then, the DCs were washed and coincubated with TCR-transduced PBMCs. A specific T cell
reactivity was seen when the TCR-transduced T cells were cocultured with the HLA-DRB1*07:01 donor
(Figure 5E). To further test our results, and to test the possibility that KRAS-mutated peptide might be presented on HLA-DRB3–5 molecules, we pulsed the 24mer peptides on HEK293T-CIITA cells transfected
with HLA-DRB1*07:01 and cocultured the cells with T cells expressing the TCR. Indeed, T cells were
specific against the HLA-DRB1*07:01 (Supplemental Figure 3E). Further, to evaluate the potential of this
potent TCR to serve as an off-the-shelf agent for cancer immunotherapy, we first assessed the expression
frequencies of KRASG12V and HLA-DRB1*07:01 in the US population. Based on the Allele Frequency Net
Database (http://www.allelefrequencies.net) (30), in White and African Americans, 25%–30% and 12.6%
of the individuals express this allele, respectively. KRASG12V hot-spot driver mutations are expressed at high
frequency in various histologies, approximately 22% of pancreatic cancer patients (COSMIC database,
http://cancer.sanger.ac.uk/cosmic); thus, given the frequencies of HLA-DRB1*07:01 and G12V among
cancer patients, this TCR would be a useful candidate for an off-the-shelf cancer immunotherapy reagent.
In summary, using our high-throughput sensitive approach, we were able to isolate a potent HLA class
II–restricted TCR targeting the shared KRASG12V mutation.

Discussion
In this study, we describe a nonbiased, high-throughput approach to identify and isolate neoantigen-reactive clones from tumor digests. Previous studies have shown that neoantigen-reactive CD4+ and CD8+ T
cells can be detected in tumor lesions (4, 5, 14, 17, 31) and that reinfusion of ex vivo expanded neoantigenreactive TILs can mediate tumor regression in metastatic cancer patients (4, 28, 32, 33). Although ACT of
metastatic melanoma patients using unselected TILs achieved a 24% CR rate and 56% ORR (3), currently,
the success in common epithelial cancers is limited. We have sought to improve the detection of neoantigen-reactive cells and shorten the time to identification of reactive TCRs for possible use in autologous
cell gene therapy. By employing our new high-throughput approach we identified T cell reactivities against
14 new unique neoantigens that were missed when TIL fragments of the patients were screened using our
standard approach.
In previous studies, several methods have been developed to identify and isolate tumor- or neoantigenreactive TILs (12, 14, 15, 17–19, 31, 34). However, a number of factors can limit their efficiency. The
frequency of neoantigen-reactive TILs can decline dramatically when cells are expanded ex vivo as a bulk
culture, possibly due to overgrowth of younger, nonreactive TILs at the expense of exhausted reactive cells.
Thus, reactive T cells present at low frequency in the excised tumor, as we showed in Pt.4078, Pt.4148, and
Pt.4127, may be missed in conventional functional TIL screens using fragment cultures. Additionally, the
antigen-experienced Temra cells, that have very low or no expression of PD-1 (19, 22), might be missed in
approaches that use the PD-1 as the sole marker for enrichment. Here, to overcome these obstacles we first
FACS-isolated T cells expressing PD-1 and/or T cell activation markers from tumor digests and expanded
them at low cell concentrations. The metastatic lesions studied in this work were excised from patients and
tumor fragments were also cultured in high-dose IL-2 and tested against mutated peptides and TMGs, as
previously described (5, 28, 33). The remainder of the excised tumors were enzymatically digested and
frozen for further testing described in this study.
We first tested our limiting-dilution approach on a tumor digest from Pt.4078. Our standard screening
of TIL fragments from Pt.4078 did not reveal reactivity against the pools of the mutated 25mer peptides
(Supplemental Figure 1A). However, when sorted TILs were cultured at 3 cells/well and expanded, 13% of
the cultures grew and could be tested. To test all of these cultures against peptide pools we had to minimize
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our screening assay to a manageable size by pooling 2 microwell cultures and testing against DCs pulsed
with 2 peptide pools. As demonstrated in Figure 2B, the functional assays of the mixed cultures showed
enhanced IFN-γ secretion against several peptide pools. As a control, we tested bulk FACS-isolated cells
using the same gating strategy (Figure 2A) and did not find reactivity against the pools. Five unique neoantigens were discovered when TILs were cocultured with DCs loaded with individual peptides (Figure
2D), and Sanger sequencing revealed that all neoantigen-reactive cultures were clonal. To determine the
frequency of neoantigen-reactive T cells in the tumor we compared these TCR sequences to sequences of
bulk, PD-1+, and PD-1– tumor-resident T cells. Interestingly, 4 TCRs were present in very low frequency
in bulk T cells and 3 of these 4 TCRs were enriched in PD-1+ sorted cells, although still found at low frequencies (Table 1). The TCR sequence from culture W8 was present in PD-1+ only and not in the bulk nor
PD-1–. Finally, the TCR from culture W7 was present in PD-1– and the unselected bulk population but not
in PD-1+, suggesting that neoantigen-reactive T cells can be found in the PD-1–CD134+ population. These
results are consistent with our previous findings that neoantigen-reactive T cells are enriched in PD-1+ T
cells (18, 19). However, some cultures, such as W7, can be missed, suggesting that the additional markers
used in our approach (CD134 or CD137) are able to improve the detection and isolation of neoantigenreactive T cells. To summarize, our 2-step high-throughput approach allowed us to detect 5 T cell clones
targeting 5 different neoantigens in this patient that were missed when TILs grown from tumor fragments
were screened by our conventional method.
We presumed that starting microwell cultures with a low number of antigen-experienced cells and further expanding them, using an antibody stimulation, will drive them to a more senescent state. To test our
assumption, we evaluated the expression of differentiation and inhibitory markers in cells from 6 cultures
of 3 patients. Five out of 6 cultures showed high expression of LAG3 and TIM-3, consistent with our
assumption (Supplemental Figure 6). We thus hypothesized that reactive TCRs introduced to autologous
PBLs can be more advantageous than using expanded microwell cultures for adoptive cell transfer. Here,
we showed that coupling a nested scPCR step with our screening step allowed us to isolate and sequence
neoantigen-reactive TCRs quickly and efficiently.
Targeting driver oncogenes using off-the-shelf therapeutic reagents is attractive since these mutations
are likely to be homogeneously expressed in cancer cells across different cancer histologies (35). We recently showed that ACT using CD8+ TILs targeting the KRASG12D mutation led to a significant antitumor
clinical response (4). Here, employing our approach on tumor samples from 2 patients enabled us to identify and isolate 4 TCRs targeting driver hot-spot mutations. Three TCRs were detected in a tumor sample
from Pt.4127 targeting TP53G245S in the context of HLA-DRB3*02:02 (Figure 4C). All 3 TCRs were specific against mutated TP53 peptide and not the WT counterpart. Since the frequency of TP53G245S is 2.8%
among all cancer patients and can be higher in several histologies (36), and the frequency of individuals
expressing the HLA-DRB3*02:02 is high (16.4% allele frequency in the White US population, http://
allelefrequencies.net), these TCRs are attractive candidates for off-the-shelf cancer immunotherapy treatments using autologous gene-engineered PBMCs.
Similar to TP53, mutations in KRAS are frequent and important for tumorigenesis of many cancers. The
hot-spot mutations in KRAS occur mainly at positions 12, 13, and 61 (28). In human cancers, KRAS mutations have been identified in approximately 90% of pancreatic ductal adenocarcinoma (PDAC) (37), and
33% in colorectal cancer (COSMIC database, http://cancer.sanger.ac.uk/cosmic). In this study, we detected
and isolated TCR from CD4+ TILs targeting KRASG12V. The G12V mutation is the second most frequent
mutation among KRAS mutations (37%, 35%, 30%, and 24% in ovarian, prostate, pancreatic, and colorectal, respectively [COSMIC database]) after KRASG12D. This TCR is a putative candidate to serve as an offthe-shelf therapeutic agent because of its high specificity for the mutated but not the WT protein (Figure
5C). Furthermore, to evaluate the potency of the isolated TCR we incubated autologous DCs with supernatant of lysed cell lines expressing KRAS mutations followed by incubation with TCR-expressing PBLs.
Although it is possible that tumor cells may express MHC class II on their surface, the predominant axis of
class II–restricted peptide presentation in the tumor microenvironment likely remains APCs (38). The results
of this experiment, as presented in Figure 4D, in addition to the observation that the TCR can be triggered
in a coreceptor-independent manner (Supplemental Figure 3C), demonstrate a high potency of the TCR.
Finally, we determined that the recognition is restricted by HLA-DRB1*07:01 using HLA-DRB1 matching
donors (Figure 5E) and verified by HLA transfection into HEK293T-CIITA cells (Supplemental Figure 3D).
The frequency of individuals that have HLA-DRB1*07:01 is relatively high in the US (25%–30% and 12.6%
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in White and African American, respectively). Thus, this TCR could be used as an off-the-shelf reagent for
TCR-gene therapy. In summary, our new high-throughput approach for sorting and culturing TILs enabled
us to isolate a rare (present at 0.056% of the rearranged TCRs in the tumor) and potent KRASG12V-targeting
TCR from a tumor digest. This approach can complement the identification of a KRAS-targeting receptor
raised by immunizing HLA transgenic mice, as reported by other members of our group (39). A previous
study showed that TGB6F1 mice, which harbor the KRASG12R mutation in their germline, are prone to develope papilloma that progress to cancer, and immunization with the G12R peptide can generate specific CD4
reactivities. Interestingly, the generation of the G12R-specific CD4+ cells was correlated with enhancement
of tumor growth (40). However, since the mutation was encoded in the germline there is a possibility that the
immunization generated CD4+ Treg cells that promoted the tumor growth.
Our findings showed enhanced detection of neoantigen-reactive TILs. In 2 patients, Pt.4078 and Pt.4148,
we isolated reactive cells that were present at a very low frequency in the tumor and were missed in TIL fragment screens (Figures 2 and 5). In the tumor sample from Pt.4127, in addition to reactivity against TP53G245S
that was found in TIL fragments we detected 3 additional neoantigen reactivities (Figure 4 and Table 2). In
the remaining samples, although we found the same number of neoantigen reactivities as found in TIL fragments, the screen revealed several different neoantigens (Table 2). As mentioned earlier, only a small portion
of the tumor was used as a source of TIL microwell cultures (while the bigger part was used to generate
fragments [NCT01174121, protocol 10-C-0166]), we speculate that utilizing our approach on a bigger tumor
sample may allow detecting additional reactivities. Furthermore, 2 of the neoantigen reactivities that were
detected by TIL fragment screening that were not detected in our method were CD8+ T cell epitopes. There
are several possible reasons we are missing the reactivities: (a) high-dose IL-2 and OKT3 are not optimal for
growing CD8+ TILs in microwell cultures in REP conditions, (b) due to the small number of cells in tumor
digests, in patients 4166 and 4217 we used CD134 alone in conjunction with PD-1 for cell isolation; however,
several studies have reported that CD137 is a better marker for CD8 cells (41, 42), (c) CD4+ and CD8+ cells
were not separated in the sort nor the culture and CD4+ cells may have overgrown in mixed cultures (3 cells/
well), and (d) in the first screen using our approach we pulse the cells with a large pool of peptides in order
to minimize the assay; this strategy can reduce the sensitivity of the screen due to HLA peptide competition.
To improve our approach we are planning to address these points by using larger tumor samples to generate
tumor digests, separating CD4+ and CD8+ cells, using additional T cell activation markers for enrichment,
and utilizing robotics in our pipeline to upgrade our high-throughput capacity.
In summary, we have developed a method that allows an enhanced and rapid identification of neoantigen-reactive TCRs for personalized TCR-gene therapy as well as the identification of TCRs targeting
hot-spot neoantigens that may be used as off-the-shelf reagents for TCR gene therapy.

Methods
Patients, tumor biopsies, and PBMCs. All samples were obtained from patients enrolled in NIH protocol
10-C-0166 (NCT01174121) and after written, informed consent was granted. One or more metastatic lesions were resected and was used for (a) whole-exome and RNA sequencing, (b) plating 24 TIL
fragments for future screening and treatment as part of the clinical protocol (11), and (c) the rest of
the resected tumor was enzymatically digested followed by mechanical tissue separation, as previously
described (19). Briefly, tumor specimens were minced under sterile conditions, followed by enzymatic
digestion (RPMI-1640 with L-glutamine [Lonza]), 1 mg/ml collagenase IV (Sigma-Aldrich), 30 U/ml
DNAse (Genentech), and antibiotics for several hours at 37°C and intermittent mechanical tissue separation using gentleMACS (Miltenyi Biotec). Tumor digests were then cryopreserved for further analysis.
Leukapheresis was performed to obtain PBMCs.
Whole-exome and RNA sequencing. Genomic DNA purification, library construction, exome capture
of approximately 20,000 coding genes, next-generation sequencing of fresh tumor embedded in optimum cutting temperature (OCT, Sakura Finetek), and a matched normal leukapheresis sample were
performed as previously described (43). An mRNA sequencing library was prepared from fresh tumors
using the Illumina TruSeq RNA library prep kit. Putative nonsynonymous mutations were defined by 3
or more exome variant reads, 7% or greater variant allele fraction (VAF) in the exome, and 10 or more
reads in the matched normal sample. Putative mutations with a variant allele frequency of greater than
10% in the tumor exome, as well as mutations that were identified in both transcriptome and exome
analyses, were initially selected for screening.
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T cell sorting and in vitro expansion. Cell sorting was carried out using the FACSJazz or FACSAria IIu
instrument (BD Biosciences). Tumor digests were rested overnight at 37°C in complete 50/50 media (1:1
mix of RPMI-1640 with L-glutamine and AIMV [Gibco] supplemented with 100 U/ml penicillin, 100 μg/
ml streptomycin, 12.5 mM HEPES, and 5% human serum) in the absence of cytokines. Bulk-sorted cells
were gated on live (PI negative), single cells, CD3+PD-1+ and/or activation markers (CD134, CD137) as
shown in Figure 1. Sorted cells were diluted and seeded in 96-well plates at 3 cells/well in REP media in
the presence of 50 ng/ml OKT3 (Miltenyi Biotec), 3,000 IU/ml IL-2 (Aldesleukin, Chiron), and 1 × 105
irradiated allogeneic feeder cells (Figure 1). On days 7 and 14, half of the medium was replaced with fresh
50/50 medium containing IL-2. Microwell cultures were tested 3–4 weeks following the initial sort.
Antibodies for flow cytometry and blocking experiments. The following fluorescently conjugated antibodies were purchased from BD Biosciences: CD3-PE/APC-H7/FITC (SK7), CD8-APC/PE-Cy7/PE (SK1),
CD4-PE/FITC/BV421 (SK3), CD137-APC/PE (4B4-1), CD134-FITC/PE (ACT35), mTCRβ-FITC/PE
(H57-597), CD14-PE (MφP9), CD80-PE (L307.4), and HLA-DR-PE-Cy7 (L243). Antibody PD-1-APC/
PE (MIH4) was from eBioscience. For HLA-blocking experiments we used pan-class II (clone IVA12), panclass I (clone W6/32), HLA-DR (clone HB55), HLA-DP (clone B7/21), and HLA-DQ (clone SPV-L3).
IFN-γ ELISPOT cocultures and flow cytometry assays to assess T cell activation. For peptide presentation, we
used 5 × 104 to 1 × 105 cells/well of autologous DCs as APCs. Crude peptides were used in the primary
screens and HPLC-grade peptides were used in the late validation tests (GenScript). Briefly, DCs were
pulsed overnight with 1–20 μg/ml peptides at 37°C in complete DC media composed of RPMI containing 5% human serum, 100 U/ml penicillin and 100 μg/ml streptomycin, 2 mM L-glutamine, 800 IU/ml
GM-CSF (Leukine), and 200 U/ml IL-4 (Peprotech). Subsequently, DCs were washed and coincubated
overnight with 2 × 104 T cells in antibody-precoated ELISPOT plates.
For IFN-γ ELISPOT assays, ELIIP plates (Millipore, MAIPSWU) were pretreated with 50 μl of 70%
ethanol per well, washed 3 times with PBS, and then coated with 50 μl of 10 μg/ml IFN-γ capture antibody
(Mabtech, clone 1-D1K) and incubated overnight at 4°C. For OKT3 controls, wells were coated with a
mixture of IFN-γ capture antibody and OKT3 (1 μg/ml). For the PMA/ionomycin control we added 1:500
diluted Cell Stimulation Cocktail (eBioscience, 00-4970-03) to T cell cultures. Prior to coculture, the plates
were washed 3 times with PBS, followed by blocking with 50/50 media for 2 hours at room temperature.
After 16–20 hours of coculture, cells were harvested from the ELISPOT plates into a standard 96-well
round-bottom plate for flow cytometry analysis, and then the ELISPOT plates were washed 5 times with
PBS plus 0.05% Tween 20 (PBS-T), and incubated for 2 hours at room temperature with 100 μl/well of
a 0.22-μm-filtered 1 μg/ml biotinylated anti–human IFN-γ detection antibody solution (Mabtech, clone
7-B6-1, diluted in 1× PBS supplemented with 0.5% FBS). The plate was then washed 3 times with PBST, followed by a 1-hour incubation with 100 μl/well of streptavidin-ALP (Mabtech, diluted 1:3,000 with
above diluent). The plate was then washed 5 times with plain PBS followed by development with 100 μl/
well of 0.45-μm-filtered BCIP/NBT substrate solution (KPL, Inc.). The reaction was stopped by rinsing
thoroughly with tap water. ELISPOT plates were scanned and counted using an ImmunoSpot plate reader
and associated software (Cellular Technologies Limited, Ltd). Expression of the T cell activation markers
CD134 and CD137 was assessed by flow cytometry at approximately 18–24 hours after stimulation. Briefly,
cells that were harvested from the ELISPOT plate were pelleted, washed with FACS buffer (1× PBS supplemented with 1% FBS and 2 mM EDTA), and then stained with the appropriate antibodies for 30 minutes,
at 4°C in the dark. Cells were washed with FACS buffer prior to acquisition on a BD FACSCanto I, BD
FACSCantoII, and BD LSRFortessa flow cytometers. All data were gated on live (PI negative), single cells.
Data analysis was carried out using FlowJo software (Tree Star).
Generation of autologous APCs. Monocyte-derived, immature DCs were generated from PBMCs using
the plastic adherence method, as previously described (5). Briefly, apheresis samples were thawed, washed,
set to 5 × 106 to 10 × 106 cells/ml with neat AIM-V media (Life Technologies) and then incubated at
approximately 1 × 106 cells/cm2 in an appropriately sized tissue culture flask and incubated at 37°C, 5%
CO2. After 90 minutes, nonadherent cells were collected, and the flasks were vigorously washed with AIMV media, and then incubated with AIM-V media for another 60 minutes. The flasks were then vigorously
washed again with AIM-V media and then the adherent cells were incubated with DC media. On day 4 or
5, DCs were collected and used or frozen for future use.
HLA blocking and HLA restriction mapping. In antibody-blocking experiments, we preincubated target
cells with 20–50 μg/ml blocking antibodies for 2–3 hours at 37°C, followed by coculture with effector
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T cells. 16–22 hours later, supernatants were harvested and IFN-γ secretion was analyzed by ELISA.
Cells were collected, labeled, and analyzed by flow cytometry. HLA restrictions were determined by
transfecting COS7 or HEK293T-CIITA cell lines with pCDNA3.1 plasmids encoding the individual
HLAs of interest. The next day, cells were washed and pulsed with mutated peptide for 2–4 hours.
Subsequently, peptides were washed and effector T cells were added. IFN-γ secretion was assessed
by ELISPOT or quantified by ELISA. At the end of the coculture, cells were collected, labeled, and
expression of CD134 and CD137 was assessed by flow cytometry.
TCR sequencing. For 5′RACE-based amplification, T cells were pelleted from TIL microwell cultures
and total RNA isolated (RNeasy Mini kit, Qiagen). Total RNA then underwent 5′RACE as directed by
the manufacturer (SMARTer RACE cDNA amplification kit, Clontech) using TCRα and -β chain constant
primers. The sequences of the α and β chain constant chain primers are: α, 5′-GCCACAGCACTGTTGCTCTTGAAGTCC; β, 5′-CAGGCAGTATCTGGAGTCATTGAG. PCR products were then isolated
by standard agarose gel electrophoresis and gel extraction (Clontech). Products were then either directly
sequenced or TOPO-TA subcloned followed by Sanger sequencing of individual colonies (Macrogen).
scPCR for TCR sequencing was performed as previously described (31). Briefly, single-cell sorting was
performed using a modified FACSAria IIu instrument based on T cell activation markers following coculture. Cells were sorted into reverse transcription PCR (RT-PCR) buffer and a series of 2 nested PCRs
were done to amplify TCRα and -β chains. The first RT and amplification reaction was performed with
a One-Step RT-PCR kit (Thermo Fisher Scientific) using multiplex PCR with multiple Vα and Vβ region
primers and one primer for Cα and Cβ regions each. The RT-PCR reaction was performed according to
the manufacturer’s instructions using the following cycling conditions: 50°C, 15 minutes; 95°C, 2 minutes;
95°C, 15 seconds, 60°C, 4 minutes × 18 cycles; 4°C. For the second amplification reaction, 3 μl from the
first RT-PCR was used as a template in total 25 μl PCR mix using HotStarTaq DNA polymerase (Qiagen)
and multiple internally nested Vα and Vβ region primers and 1 internally nested primer for Cα and Cβ
regions each (final concentration of each primer was 0.6 μM). The cycling conditions were 95°C, 15 minutes; 94°C, 30 seconds, 50°C, 30 seconds, 72°C, 1 minute × 50 cycles; 72°C, 10 minutes; 4 °C. The PCR
products were purified and sequenced by the Sanger method with internally nested Cα and Cβ region primers by GenScript.
TCR-Vβ deep sequencing was performed by immunoSEQ (Adaptive Biotechnologies) on genomic
DNA isolated from TIL microwell cultures or frozen tumor.
TCR construction and viral transduction. Construction of the TCRs was done by fusing the V-D-J of the
Vβ regions to the mouse TCRβ constant chain, and the TCRα V-J regions to the mouse TCRα constant
chains. The chains were separated by a furin-SGSG-P2A linker. The chains were then synthesized and
subcloned into the pMSGV1 retroviral vector (GenScript).
Viral transduction was performed as described previously (5). Briefly, 2 days prior to transduction
PBMCs were cultured and stimulated in 24-well plates at 2 × 106 cells/well in 50/50 media in the presence
of 300 IU/ml IL-2 and 50 ng/ml OKT3. To generate transient retroviral supernatants, pMSGV1 encoding
the TCRs (2 μg/well) and the envelope-encoding plasmid pRD114 (1.4 μg/well) were cotransfected using
Lipofectamine 2000 (Life Technologies) into the retroviral packaging cell line HEK293GP (1 × 106 cells per
well of 6-well poly-D-lysine–coated plates, plated the day prior to transfection in the absence of antibiotics). Retroviral supernatants were collected at 48 hours after transfection, diluted 1:1 with DMEM media,
and then centrifuged onto Retronectin-coated (10 μg/ml, Takara), non–tissue culture–treated 6-well plates
at 2,000 g for 2 hours at 32°C. Activated T cells (2 × 106 cells/well, at 0.5 × 106 cells/ml in IL-2–containing
T cell media) were then spun onto the retrovirus plates for 10 minutes at 300 g (low acceleration and brake).
Activated T cells were transduced overnight, removed from the plates, and further cultured in 50/50 media
containing 300 IU/ml IL-2. GFP and mock-transduction controls were included in transduction experiments. Cells were typically assayed 10–14 days after retroviral transduction.
Study approval. All patient samples were obtained in the course of a National Cancer Institute Institutional Review Board–approved clinical trial, and patients provided informed consent.
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